
Vivek Subbiah/LinkedIn
May 21, 2025, 12:22
Vivek Subbiah: Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a post on LinkedIn:
“Happy Clinical Trials Day!
Honored to work alongside an incredible team of investigators dedicated to ending cancer. Grateful for the innovation, perseverance, and hope that fuels every study & every clinical trial.
Looking forward to ASCO25.”
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 21, 2025, 12:14
May 21, 2025, 12:07
May 21, 2025, 11:32
May 21, 2025, 09:58
May 21, 2025, 08:51